MANGIFERIN STUDIES CONFIRMS ITS EFFECTIVENESS AGAINST HIV-1

MANGIFERIN STUDIES CONFIRMS ITS EFFECTIVENESS AGAINST HIV-1

The development of antiretroviral therapies to fight human immunodeficiency virus type 1 (HIV-1) infection has led to a significant decrease in mortality and morbidity among infected populations. Nevertheless, the emergence of viral resistant strains to drugs is causing serious clinical and public health problems throughout the world. Resistance to one drug often results in cross-resistance to others in the same class.

Mangiferin (1,3,6,7-tetrahydroxy-C2-β-D-glucoside, Figure 1) is found in many plants, including Anacardiaceae and Rhizoma anemarrhenae.  This chemical is a constituent of folk medicines and can be synthesized easily. In the present study, Mangiferin was confirmed to have good anti-HIV-1 activity. 

(Fig 1: Structure of mangiferin.)

Mangiferin exhibited low cytotoxicity and good inhibitory activity on HIV-1 replication in a dose-dependent manner. The antiviral activities of Mangiferin were observed to primary HIV-1 isolate and resistant strains also. Mechanism studies revealed that Mangiferin might inhibit the HIV-1 protease, and is still effective against HIV peptidic protease inhibitor resistant strains. Furthermore, three pharmacophore elements of Mangiferin displayed a high degree of matching with the reference pharmacophore model from approved PIs and as a key role in binding HIV-1RF PR. Though the anti-HIV-1 activities were not as good as approved PIs, our results suggest that Mangiferin may be a novel NPPI with an original structure that represents an effective drug development strategy for combating drug resistance.

Besides its effectiveness towards HIV-1, Mangiferin has been praised as a miracle bioactive compound against lifestyle related disorders. Especially it has been used in various Supplement and Pharmaceutical formats to treat disease related to HPV virus such as Zona.

(Some Products with Mangiferin)